Diacerein (DB11994): A Comprehensive Pharmacological and Clinical Monograph

1.0 Executive Summary

Diacerein is a small molecule drug of the anthraquinone class, developed as a symptomatic slow-acting drug for osteoarthritis (SYSADOA).[1] Its therapeutic activity is mediated by its active metabolite, rhein, which exerts a unique mechanism of action centered on the inhibition of the pro-inflammatory interleukin-1β (IL-1β) pathway. This mode of action distinguishes it from traditional non-steroidal anti-inflammatory drugs (NSAIDs), as it does not involve the inhibition of prostaglandin synthesis.[3] In its approved indication for osteoarthritis of the hip and knee, clinical evidence demonstrates a modest but statistically significant effect on pain reduction, characterized by a slow onset of action and a notable "carryover effect" where benefits persist after treatment cessation.[1]

However, the clinical utility of oral Diacerein is significantly limited by a challenging safety and tolerability profile. The most prominent adverse event is frequent, often severe, diarrhea, a direct consequence of its anthraquinone structure and pharmacokinetic properties.[1] Furthermore, post-marketing surveillance has revealed a risk of rare but serious hepatotoxicity.[6] These safety concerns have led to significant regulatory restrictions, including recommendations from the European Medicines Agency (EMA) against its use in patients over 65 and in those with liver disease.[3] The drug is not approved by the U.S. Food and Drug Administration (FDA) for osteoarthritis.[7]

In a compelling example of drug repurposing, Diacerein is being successfully re-evaluated as a topical therapy for the rare genetic disorder Epidermolysis Bullosa (EB). In this context, its potent local anti-inflammatory effects can be leveraged while circumventing the systemic toxicities associated with oral administration.[8] This investigational use has earned it an Orphan Drug designation from the FDA, suggesting that the future of Diacerein may lie not in its original indication but in a targeted application for a high-unmet-need rare disease.[10]

2.0 Identification and Physicochemical Properties

2.1 Nomenclature and Identifiers

The compound is universally identified by its International Nonproprietary Name (INN), Diacerein.[11] Its chemical identity is precisely defined by several systematic names according to IUPAC nomenclature, including 4,5-diacetyloxy-9,10-dioxoanthracene-2-carboxylic acid and 4,5-bis(acetyloxy)-9,10-dihydro-9,10-dioxo-2-anthracenecarboxylic acid.[11]

Throughout its development and in scientific literature, Diacerein has been referred to by various synonyms and codes, such as Diacetylrhein, Diacerhein, DAR, AC-201, and SF-277.[13] Commercially, it is marketed under brand names including Artrodar and Fisiodar.[7] For unambiguous identification across global databases, it is assigned a unique set of identifiers, which are consolidated in Table 2.1.

2.2 Chemical Structure and Properties

Diacerein is a synthetic organic compound belonging to the anthraquinone chemical class, a family of compounds based on a tricyclic aromatic quinone structure.[2] This chemical backbone is fundamental to its biological activity and is also implicated in its characteristic adverse effect profile, particularly its laxative effects.[1]

The molecular formula of Diacerein is C19​H12​O8​, corresponding to an average molecular weight of approximately 368.3 g/mol.[3] In its pure form, it presents as a yellow or light yellow crystalline solid or powder.[16] Its solubility is a key physicochemical characteristic influencing its formulation and pharmacokinetics; it is practically insoluble in water, with reported values around 0.01 mg/mL, but is sparingly soluble in organic solvents such as dimethyl sulfoxide (DMSO) and methanol.[3]

Table 2.1: Key Identifiers and Physicochemical Properties of Diacerein

Property / Identifier	Value	Source(s)
Generic Name	Diacerein	14
DrugBank ID	DB11994	11
CAS Number	13739-02-1	13
Systematic (IUPAC) Name	4,5-diacetyloxy-9,10-dioxoanthracene-2-carboxylic acid	12
Molecular Formula	C19​H12​O8​	14
Average Molecular Weight	368.297 g/mol	3
Physical Appearance	Yellow powder or crystalline solid	16
ATC Code	M01AX21	3
PubChem CID	26248	3
FDA UNII	4HU6J11EL5	3
Water Solubility	Practically insoluble (0.01 mg/mL at 20 °C)	3

3.0 Pharmacology and Mechanism of Action

3.1 Pharmacodynamics and Active Metabolite

Diacerein functions as a prodrug, meaning it is pharmacologically inactive until it is metabolized in the body. Following oral administration, it undergoes complete and rapid deacetylation in the gut wall and liver, yielding its sole active metabolite, rhein.[1] All subsequent anti-inflammatory and chondroprotective effects of the drug are attributable to the actions of rhein. This metabolic activation is a critical and defining feature of its pharmacological profile.

3.2 Modulation of the Interleukin-1β (IL-1β) Pathway

The principal mechanism of action of Diacerein, via rhein, is the potent and multi-level inhibition of the pro-inflammatory cytokine Interleukin-1β (IL-1β). IL-1β is a pivotal mediator in the pathogenesis of osteoarthritis, driving inflammation, cartilage degradation, and pain.[1] The inhibitory action is comprehensive and occurs through several distinct mechanisms:

1. Inhibition of IL-1β Activation: Rhein reduces the production and activity of IL-1 converting enzyme (ICE), also known as caspase-1. This enzyme is essential for cleaving the inactive precursor, pro-IL-1β, into its biologically active form.[1]
2. Downregulation of IL-1 Receptors: It decreases the expression of IL-1 receptors on the surface of chondrocytes, thereby reducing the sensitivity of these cartilage cells to the damaging effects of the cytokine.[1]
3. Upregulation of IL-1 Antagonism: It indirectly stimulates the production of IL-1 receptor antagonist (IL-1Ra), a naturally occurring protein that competes with IL-1β for receptor binding sites, effectively blocking its signaling.[1]

This multifaceted blockade of the IL-1β system provides a robust mechanistic foundation for its anti-inflammatory effects and its potential to modify the underlying disease process in osteoarthritis.[13]

3.3 Chondroprotective Effects: Anti-Catabolic and Pro-Anabolic Actions

Beyond its anti-inflammatory properties, Diacerein exhibits characteristics of a Disease-Modifying Osteoarthritis Drug (DMOAD) through direct effects on cartilage homeostasis.[1] These effects are twofold:

• Anti-Catabolic Action: Rhein actively reduces the breakdown of cartilage matrix. It achieves this by decreasing the expression and activity of key degradative enzymes, particularly matrix metalloproteinases (MMPs) such as MMP-1 (collagenase) and MMP-3 (stromelysin).[13] Concurrently, it upregulates the production of Tissue Inhibitor of Matrix Metalloproteinases (TIMPs), which further neutralizes MMP activity.[13]
• Pro-Anabolic Action: Rhein stimulates chondrocytes to synthesize essential components of the cartilage extracellular matrix. This includes promoting the production of proteoglycans, aggrecan, hyaluronic acid, and type II collagen, thereby supporting cartilage repair and structural integrity.[1]

Furthermore, studies have shown that Diacerein can exert protective effects against the pathological remodeling of the subchondral bone, an important component of the osteoarthritic joint unit.[1]

3.4 Classification and Distinction from NSAIDs

Diacerein is classified as a Symptomatic Slow-Acting Drug in Osteoarthritis (SYSADOA), also referred to as a Slow-Acting Drug for Osteoarthritis (SADOA).[1] This classification reflects two key clinical characteristics: a delayed onset of therapeutic effect, which may take several weeks to become apparent, and a persistent "carryover" effect, where clinical benefits are maintained for a period after the drug is discontinued.[1]

The most critical distinction lies in its mechanism compared to that of NSAIDs. Unlike NSAIDs, Diacerein does not inhibit the cyclooxygenase (COX) enzymes and therefore does not interfere with prostaglandin synthesis.[3] This fundamental difference explains its divergent safety profile, notably the significantly lower risk of prostaglandin-mediated adverse effects such as gastrointestinal ulceration, renal impairment, and cardiovascular events that are major concerns with long-term NSAID use.[20] While NSAIDs provide rapid symptomatic relief by targeting inflammation and pain pathways, Diacerein's mechanism targets the upstream cytokine signaling that drives the core catabolic processes of osteoarthritis, providing a theoretical basis for its potential to modify the disease course rather than merely alleviating symptoms.

4.0 Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The pharmacokinetic profile of Diacerein is defined by its behavior as a prodrug, with systemic measurements focused on its active metabolite, rhein.

4.1 Absorption and Bioavailability

Following oral administration, Diacerein has a moderate bioavailability, estimated to be between 50% and 60%.[13] It undergoes complete presystemic metabolism via double deacetylation in the gastrointestinal tract and liver, meaning only the active metabolite rhein is detected in systemic circulation.[13]

The co-administration of food has a significant impact on absorption kinetics. A high-fat meal delays the rate of absorption, resulting in a lower peak plasma concentration (Cmax​) and a longer time to reach that peak (Tmax​).[26] However, the overall extent of absorption, as measured by the area under the curve (AUC), remains unaffected by food.[26] This pharmacokinetic property provides the rationale for the clinical recommendation to administer Diacerein with food, as slowing the absorption rate may improve gastrointestinal tolerability.[6]

4.2 Distribution

Rhein is extensively bound to plasma proteins, with approximately 99% bound primarily to albumin.[3] This high degree of protein binding can influence its distribution into tissues and its potential for drug-drug interactions. The volume of distribution for rhein is reported to be in the range of 15 to 60 liters.[13]

4.3 Metabolism

The metabolic pathway of Diacerein is straightforward. The first and most critical step is the complete conversion of the prodrug to rhein.[3] Subsequently, rhein undergoes Phase II conjugation reactions in the liver to form more water-soluble metabolites, rhein glucuronide and rhein sulfate, which facilitates their elimination from the body.[3]

4.4 Excretion

The primary route of elimination for rhein and its conjugates is through the kidneys.[3] Animal studies in rats suggest that approximately 37% of a dose is excreted in the urine and 53% in the feces.[13] The elimination half-life (

t1/2​) of rhein in plasma is approximately 4 to 10 hours.[3]

The pharmacokinetic profile provides a direct explanation for both the therapeutic action and the primary adverse effect of Diacerein. While the prodrug design ensures systemic delivery of the active anti-inflammatory metabolite rhein, the incomplete absorption of the drug from the upper gastrointestinal tract is a critical factor. The unabsorbed portion of the drug and its metabolite, which belong to the laxative-acting anthraquinone class, reaches the colon. There, it exerts a local irritant effect, leading to the characteristic and dose-limiting side effect of diarrhea.[1] This clear link between pharmacokinetics and adverse events has directly motivated research into novel formulations, such as gastroretentive systems, designed to enhance absorption in the upper GI tract and thereby minimize the amount of active substance reaching the colon.[29]

Table 4.1: Summary of Pharmacokinetic Parameters for Diacerein/Rhein

Parameter	Value	Source(s)
Bioavailability	50-60%	13
Tmax​ (fasted)	~2.6 hours	26
Tmax​ (fed)	~3.8 hours	26
Cmax​ (fasted, 50 mg dose)	~4471 ng/mL	26
Cmax​ (fed, 50 mg dose)	~3225 ng/mL	26
Elimination Half-life (t1/2​)	4-10 hours	3
Plasma Protein Binding	~99%	3
Route of Elimination	Primarily Renal	3

5.0 Clinical Efficacy and Therapeutic Applications

5.1 Primary Indication: Osteoarthritis of the Hip and Knee

5.1.1 Critical Review of Clinical Evidence

Diacerein is approved in several countries for the symptomatic treatment of osteoarthritis (OA) affecting the hip or knee.[6] Its therapeutic effect is characterized as delayed, and it is noted to be less effective in patients with rapidly progressive forms of hip OA.[6]

A substantial body of clinical evidence, including multiple randomized controlled trials and meta-analyses, has established a consistent, albeit modest, efficacy profile. A 2014 Cochrane systematic review concluded that Diacerein has a "small beneficial effect on pain" when compared to placebo.[3] This effect was quantified as an average 9-point greater reduction in pain on a 100-point visual analogue scale (VAS) over treatment periods of 3 to 36 months.[24] In contrast, its effect on improving physical function has generally not reached statistical significance in these analyses.[24] There is also low-quality evidence suggesting that Diacerein may slightly slow the rate of joint space narrowing (a marker of structural progression) in the hip, though a similar effect has not been demonstrated in the knee.[24] When compared directly with NSAIDs, Diacerein demonstrates comparable efficacy for pain relief during the active treatment phase.[5]

5.1.2 The "Carryover Effect"

A distinguishing clinical feature of Diacerein and other SYSADOAs is the presence of a "carryover effect." This refers to the sustained therapeutic benefit, particularly pain relief, that persists for several weeks to months after the cessation of treatment.[1] This phenomenon stands in stark contrast to the rapid waning of effects seen upon discontinuation of NSAIDs.[33] The carryover effect lends clinical support to the hypothesis that Diacerein's mechanism involves a deeper, disease-modifying action on cartilage and synovial tissue, rather than purely symptomatic modulation.

5.2 Investigational and Off-Label Applications

5.2.1 Epidermolysis Bullosa (EB)

A significant and promising new direction for Diacerein is its repurposing as a topical therapy for Epidermolysis Bullosa (EB), a group of rare and severe genetic blistering skin disorders.[8] Specifically, a 1% ointment formulation (coded as AC-203 or CCP-020) is under active investigation for Epidermolysis Bullosa Simplex (EBS).[35]

The therapeutic rationale in EB stems from Diacerein's ability to inhibit IL-1β. In EBS, mutations in keratin genes (KRT5/KRT14) lead to a pathogenic inflammatory feedback loop involving IL-1β and keratin 14 overexpression, which destabilizes the epidermis.[34] By disrupting this cycle locally, topical Diacerein has been shown to reduce blister formation.[34] Clinical trials have yielded promising results; a phase 2/3 crossover study demonstrated a statistically significant reduction in blister counts in patients treated with 1% Diacerein cream compared to placebo.[37]

This potential has been recognized by regulatory agencies. The U.S. FDA granted Diacerein Orphan Drug designation in November 2018 and Fast Track designation for the treatment of EB, highlighting the high unmet medical need.[8] Ongoing international phase 2/3 trials are further evaluating its long-term efficacy and safety.[35] There is also a case report suggesting potential efficacy in recessive dystrophic EB (RDEB), a different subtype of the disease.[39]

This clinical development path highlights a critical therapeutic pivot. The oral formulation for osteoarthritis is constrained by a narrow therapeutic window due to modest efficacy and significant systemic side effects. In contrast, the topical formulation for EB offers a solution to this risk-benefit challenge. By delivering the drug directly to the skin, it maximizes local anti-inflammatory efficacy at the site of pathology while minimizing systemic absorption, thereby avoiding the dose-limiting gastrointestinal and hepatic toxicities associated with oral use.[8] This change in administration route effectively unlocks the drug's potent mechanism for a new indication where its benefits can be realized with a much more favorable safety profile.

5.2.2 Metabolic Disorders

Diacerein has also been investigated for its potential role in metabolic diseases. It has been studied for the treatment of Type 2 Diabetes Mellitus and Metabolic Dysfunction-associated Steatohepatitis (MASH).[13] A completed Phase 3 clinical trial (NCT02242149) was conducted to evaluate its efficacy on glycemic control and liver fat content in subjects with Type 2 Diabetes, suggesting interest in its potential systemic metabolic effects.[7]

6.0 Safety, Tolerability, and Risk Management

The use of oral Diacerein is defined as much by its safety profile as by its efficacy. The risks associated with its use have led to significant restrictions and require careful patient selection and monitoring.

6.1 Adverse Effect Profile

6.1.1 Gastrointestinal Effects

The most frequently reported adverse events are gastrointestinal in nature. Diarrhea is classified as a "very common" side effect, affecting more than 1 in 10 patients, with abdominal pain also being very common.[1] Meta-analyses have calculated the risk ratio for developing diarrhea with Diacerein versus placebo to be approximately 3.5, with some studies reporting that up to 39% of patients experience at least one episode.[1]

These effects are typically mild to moderate in severity, tend to occur within the first two to four weeks of initiating therapy, and often subside with continued treatment.[1] However, severe cases of diarrhea have been reported, which can lead to complications such as dehydration and electrolyte imbalances, a particular concern in elderly patients.[1]

6.1.2 Hepatotoxicity

A less frequent but more serious risk associated with Diacerein is hepatotoxicity. Post-marketing surveillance has identified cases of acute liver injury, including clinically significant elevations in serum hepatic enzymes and cases of hepatitis.[3] Most of these events occurred within the first few months of treatment. Although preclinical toxicology studies did not identify the liver as a target organ for toxicity, the mechanism of liver injury in humans is suspected to be idiosyncratic.[1] This risk has prompted regulatory agencies to issue strong warnings and contraindicate its use in patients with liver disease.[3]

6.1.3 Other Reactions

• Dermatological: Common skin reactions, affecting up to 1 in 10 people, include pruritus (itching), rash, and eczema.[1]
• Urine Discoloration: A benign but noticeable side effect is an intense yellow or pink discoloration of the urine. This is caused by the renal excretion of rhein metabolites and has no clinical significance or pathological implication.[3]

Table 6.1: Incidence of Key Adverse Events from Clinical Trials (Diacerein vs. Placebo)

Adverse Event	Diacerein Incidence	Placebo Incidence	Absolute Risk Increase	Risk Ratio (95% CI)	Source(s)
Diarrhea	36 per 100 patients	10 per 100 patients	26%	3.52 (2.42 - 5.11)	1
Any Adverse Event	42 per 100 patients	18 per 100 patients	24%	-	42
Withdrawal due to AE	18 per 100 patients	13 per 100 patients	5%	1.29 (0.83 - 2.01)	24

6.2 Contraindications and High-Risk Populations

Based on its safety profile, the use of Diacerein is subject to several important restrictions:

• Liver Disease: It is strictly contraindicated in patients with any current or past history of liver disease.[6]
• Elderly Patients: The EMA recommends that Diacerein not be used in patients older than 65 years, primarily due to the increased risk of severe complications from diarrhea, such as dehydration.[3]
• Pregnancy and Lactation: Diacerein is not recommended for use during pregnancy or while breastfeeding.[3]

7.0 Drug and Food Interactions

The safety of Diacerein is influenced by its potential for interactions with other drugs, as well as with food and alcohol. The overall risk profile can be understood as a combination of a predictable, mechanism-based gastrointestinal effect, a rare but serious idiosyncratic hepatic effect, and a broad potential for pharmacokinetic drug-drug interactions. This last category is particularly important in the typical elderly osteoarthritis patient, who is often on multiple concurrent medications.

7.1 Clinically Significant Interactions

• Diuretics and Cardiac Glycosides: The diarrhea induced by Diacerein can lead to dehydration and hypokalemia (low potassium levels). When used concurrently with diuretics (e.g., furosemide, hydrochlorothiazide), this risk is amplified. The resultant hypokalemia is of particular concern in patients taking cardiac glycosides (e.g., digoxin), as it significantly increases the risk of cardiac arrhythmias.[6]
• Laxatives: The concomitant use of any laxative medication should be avoided, as it will potentiate the diarrheal side effect of Diacerein.[4]
• Antacids: Co-administration with antacids containing aluminum hydroxide or magnesium hydroxide may decrease the absorption of Diacerein and should be managed accordingly.[41]

7.2 Metabolic Interactions

Pharmacokinetic data suggest that Diacerein and its active metabolite rhein can inhibit various metabolic enzymes, including members of the Cytochrome P450 (CYP) 3A subfamily.[44] This creates a broad potential for drug-drug interactions by decreasing the metabolism of co-administered drugs that are substrates for these enzymes. This can lead to elevated plasma concentrations and an increased risk of toxicity for a wide range of medications. The list of potentially affected drugs is extensive and includes agents from many common therapeutic classes, such as anticoagulants (acenocoumarol, apixaban), analgesics (acetaminophen, where hepatotoxic risk may be increased), antidepressants (amitriptyline), and antidiabetic agents (acetohexamide).[14]

7.3 Food and Alcohol Interactions

• Food: As established in the pharmacokinetics section, Diacerein should be administered with food. This practice is recommended to slow the rate of absorption, which can improve gastrointestinal tolerability by blunting the peak plasma concentration of rhein.[6]
• Alcohol: Patients should be advised to limit or avoid alcohol consumption while taking Diacerein. This is a precautionary measure to minimize the potential for additive hepatotoxic effects and reduce the overall risk of liver damage.[6]

8.0 Regulatory Status and Dosing Recommendations

8.1 Global Regulatory Landscape

The regulatory status of Diacerein varies significantly across different regions, reflecting divergent assessments of its benefit-risk profile for osteoarthritis.

• European Union: Diacerein is authorized for use in some individual EU member states. However, following a comprehensive review in 2014, the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) and the Co-ordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) endorsed significant restrictions on its use to manage the risks of diarrhea and hepatotoxicity. The regulators concluded that the benefit-risk balance remained favorable only if these new restrictions were implemented.[3] It is not approved via the EMA's centralized procedure.[7]
• United States: Diacerein is not approved by the U.S. FDA for the treatment of osteoarthritis.[7] Its primary regulatory standing in the U.S. is through its designation as an Orphan Drug for the treatment of Epidermolysis Bullosa, granted in 2018.[10]
• Other Regions: The drug is approved and marketed in several Asian countries.[3]

8.2 Dosing and Administration

The following dosing recommendations apply to the approved indication of symptomatic treatment of osteoarthritis of the hip and knee. Treatment should only be initiated and supervised by physicians experienced in managing osteoarthritis.[6]

• Initial Dose: To improve initial tolerability and mitigate the risk of severe diarrhea, treatment should begin with a starting dose of 50 mg once daily, taken with the evening meal, for the first 2 to 4 weeks.[3]
• Maintenance Dose: After the initial period, the dose should be increased to the recommended maintenance dose of 50 mg twice daily.[3]
• Administration: The capsules should be taken with food (one with breakfast and the other with the evening meal) and swallowed whole with a glass of water, without being opened or crushed.[6]

9.0 Conclusion and Expert Synthesis

Diacerein occupies a complex and evolving position in the therapeutic landscape. As an oral agent for osteoarthritis, it is a drug defined by a compelling mechanistic rationale that has been largely overshadowed by a challenging clinical profile. Its unique IL-1β inhibitory action offers a theoretical advantage over traditional NSAIDs by targeting the underlying pathophysiology of cartilage degradation. However, this potential has not translated into superior clinical efficacy, with studies consistently showing only a modest benefit for pain relief. This limited efficacy is difficult to balance against a significant safety and tolerability burden, dominated by a high incidence of diarrhea and the rare but serious risk of idiosyncratic hepatotoxicity. Consequently, its role in osteoarthritis has been curtailed by regulatory bodies, confining it to a niche population where other first-line agents are contraindicated.

In stark contrast, the repurposing of Diacerein as a topical formulation for Epidermolysis Bullosa represents a remarkable therapeutic pivot. This strategic shift is a salient example of modern pharmaceutical development, where a deep understanding of a drug's mechanism can be applied to a new disease context. By changing the route of administration, developers have successfully uncoupled the drug's potent local anti-inflammatory effects from the systemic toxicities that limited its original application. This approach allows the targeted delivery of the active molecule to the site of pathology, maximizing benefit while minimizing risk.

In conclusion, while Diacerein's journey as a systemic treatment for the widespread condition of osteoarthritis appears to be one of limited and declining utility, its future as a targeted, topically delivered orphan drug for a severe rare disease is highly promising. This evolution underscores a fundamental principle in pharmacology: the ultimate value of a molecule is determined not just by its intrinsic mechanism, but by the precision with which that mechanism can be applied to a specific clinical problem.

Works cited

1. Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO - PMC, accessed September 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4756045/
2. www.ema.europa.eu, accessed September 6, 2025, https://www.ema.europa.eu/en/medicines/human/referrals/diacerein-containing-medicines-oral-administration#:~:text=Diacerein%20is%20a%20slow%2Dacting,and%20pain%20in%20the%20joints)..&sa=D&source=editors&ust=1757145230468163&usg=AOvVaw39auVnSPNlgRLpazrtwv96)
3. Diacerein - Wikipedia, accessed September 6, 2025, https://en.wikipedia.org/wiki/Diacerein
4. What is Diacerein used for? - Patsnap Synapse, accessed September 6, 2025, https://synapse.patsnap.com/article/what-is-diacerein-used-for
5. A meta-analysis of controlled clinical studies with diacerein in the treatment of osteoarthritis, accessed September 6, 2025, https://pubmed.ncbi.nlm.nih.gov/17000948/
6. Diacerein Art 31, accessed September 6, 2025, https://www.ema.europa.eu/en/documents/referral/diacerein-article-31-referral-annex-iii_en.pdf
7. diacerein | Ligand page - IUPHAR/BPS Guide to PHARMACOLOGY, accessed September 6, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=clinical&ligandId=10800
8. Diacerein 1% Ointment for Epidermolysis Bullosa Receives Fast Track Designation, accessed September 6, 2025, https://www.hcplive.com/view/diacerein-1-ointment-epidermolysis-bullosa-receives-fast-track-designation
9. For Generalized Severe EBS, Diacerein Ointment Shows Potential, Study Finds, accessed September 6, 2025, https://epidermolysisbullosanews.com/news/diacerein-ointment-potentially-safe-treatment-generalized-severe-ebs-study/
10. Search Orphan Drug Designations and Approvals - accessdata.fda ..., accessed September 6, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=660318
11. DIACEREIN - precisionFDA, accessed September 6, 2025, https://precision.fda.gov/ginas/app/ui/substances/70046fe2-7cc5-45ce-bc48-4e0872481cf3
12. diacerein | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed September 6, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10800
13. Diacerein - PubChem, accessed September 6, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Diacerein
14. Diacerein: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 6, 2025, https://go.drugbank.com/drugs/DB11994
15. Diacerein (DAR, Diacerhein, 4,5-Diacetylrhein, SF 277, CAS Number: 13739-02-1), accessed September 6, 2025, https://www.caymanchem.com/product/11710/diacerein
16. Diacerein | 13739-02-1 - ChemicalBook, accessed September 6, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB0755179.htm
17. Diacerein 13739-02-1 | TCI AMERICA - TCI Chemicals, accessed September 6, 2025, https://www.tcichemicals.com/US/en/p/D4061
18. Diacerein =95 HPLC 13739-02-1 - Sigma-Aldrich, accessed September 6, 2025, https://www.sigmaaldrich.com/US/en/product/sigma/d9302
19. Diacerein | CAS 13739-02-1 | SCBT - Santa Cruz Biotechnology, accessed September 6, 2025, https://www.scbt.com/p/diacerein-13739-02-1
20. Diacerein- A gold standard analgesic in management of osteoarthritis - Indian J Clin Anaesth, accessed September 6, 2025, https://ijca.in/archive/volume/7/issue/1/article/19825
21. What is the effect of Diacerein 50 mg? - Vinmec, accessed September 6, 2025, https://www.vinmec.com/eng/blog/what-is-diacerein-50-mg-used-for-en
22. AB0058 The Disease Modifying Osteoarthritis Drug Diacerein is Able to Antagonize PRO Inflammatory State of Chondrocytes under Mild Mechanical Stimuli, accessed September 6, 2025, https://ard.bmj.com/content/73/Suppl_2/823.2
23. The effects of orally administered diacerein on cartilage and subchondral bone in an ovine model of osteoarthritis. | The Journal of Rheumatology, accessed September 6, 2025, https://www.jrheum.org/content/28/4/825
24. Diacerein for osteoarthritis | Cochrane, accessed September 6, 2025, https://www.cochrane.org/evidence/CD005117_diacerein-osteoarthritis
25. Diacerein versus non-steroidal anti-inflammatory drugs in the treatment of knee osteoarthritis: a meta-analysis - PMC, accessed September 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10114432/
26. The effect of food intake on the pk of rhein released from diacerein - ResearchGate, accessed September 6, 2025, https://www.researchgate.net/publication/340469456_The_effect_of_food_intake_on_the_pk_of_rhein_released_from_diacerein
27. The effect of food intake on the pk of rhein released from diacerein - SciELO, accessed September 6, 2025, https://www.scielo.br/j/bjps/a/J9MmgDps5CyNx4QKJXXTnyw/
28. Annex I List of the names, pharmaceutical form, strength of the medicinal products, route of administration, marketing authorisation holders in the Member States, accessed September 6, 2025, https://ec.europa.eu/health/documents/community-register/2014/20140904128570/anx_128570_en.pdf
29. Development and Pharmacokinetic Evaluation of New Oral Formulations of Diacerein | Request PDF - ResearchGate, accessed September 6, 2025, https://www.researchgate.net/publication/280060703_Development_and_Pharmacokinetic_Evaluation_of_New_Oral_Formulations_of_Diacerein
30. Diacerein for osteoarthritis - PMC - PubMed Central, accessed September 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10712695/
31. A Meta-analysis of Controlled Clinical Studies With Diacerein in the Treatment of Osteoarthritis - Caldic Magistral, accessed September 6, 2025, https://magistralbr.caldic.com/storage/product-files/1225969944.pdf
32. Review: diacerein is more effective than placebo and is as effective as NSAIDs for knee and hip osteoarthritis | BMJ Evidence-Based Medicine, accessed September 6, 2025, https://ebm.bmj.com/content/12/3/74
33. Diacerein Found More Effective Than NSAIDs in Osteoarthritis - MDEdge, accessed September 6, 2025, https://www.mdedge.com/content/diacerein-found-more-effective-nsaids-osteoarthritis
34. Topical diacerein for epidermolysis bullosa: a randomized controlled pilot study - PMC, accessed September 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3655927/
35. Clinical Trials - EB Research Partnership, accessed September 6, 2025, https://www.ebresearch.org/clinical-trials.html
36. Topical Diacerein Ointment for Epidermolysis Bullosa Simplex: A Review, accessed September 6, 2025, https://www.skintherapyletter.com/dermatology/diacerein-epidermolysis-bullosa-simplex-2/
37. Diacerein orphan drug development for epidermolysis bullosa simplex: A phase 2/3 randomized, placebo-controlled, double-blind clinical trial - PubMed, accessed September 6, 2025, https://pubmed.ncbi.nlm.nih.gov/29410318/
38. An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS) | Clinical Research Trial Listing - CenterWatch, accessed September 6, 2025, https://www.centerwatch.com/clinical-trials/listings/NCT06073132/an-international-multicenter-randomized-double-blind-parallel-group-vehicle-controlled-phase-2-3-study-with-open-label-extension-evaluating-the-efficacy-and-safety-of-diacerein-1-ointment-for-the-treatment-of-generalized-epidermolysis-bullosa-simplex-ebs
39. Arthritis ointment diacerein heals chronic wounds in girl with RDEB, accessed September 6, 2025, https://epidermolysisbullosanews.com/news/arthritis-cream-diacerein-effective-girl-hard-treat-rdeb/
40. Diacerein Completed Phase 3 Trials for Metabolic Dysfunction-associated Steatohepatitis (MASH) / Type 2 Diabetes Mellitus Treatment - DrugBank, accessed September 6, 2025, https://go.drugbank.com/drugs/DB11994/clinical_trials?conditions=DBCOND0161012%2CDBCOND0029752&phase=3&purpose=treatment&status=completed
41. Diacerein - Uses, Dosage, Side Effects, Price, Composition | Practo, accessed September 6, 2025, https://www.practo.com/medicine-info/diacerein-83-api
42. Diacerein for osteoarthritis | Request PDF - ResearchGate, accessed September 6, 2025, https://www.researchgate.net/publication/7335147_Diacerein_for_osteoarthritis
43. www.apollopharmacy.in, accessed September 6, 2025, https://www.apollopharmacy.in/salt/Diacerein#:~:text=Drug%2DDrug%20Interaction%3A%20Diacerein%20may,the%20risk%20of%20liver%20damage.
44. Showing BioInteractions for Diacerein (DB11994) | DrugBank Online, accessed September 6, 2025, https://go.drugbank.com/drugs/DB11994/biointeractions
45. Diacerein-containing medicines for oral administration - referral, accessed September 6, 2025, https://www.ema.europa.eu/en/medicines/human/referrals/diacerein-containing-medicines-oral-administration